| 50419-0344-05 | Ultravist 300Bayer HealthCare Pharmaceuticals Inc. | 50 × 10 | 50 | 500 | $93.00 | ASP | Q1 2021 – Q4 2026 | ListedUltravist |
|---|
| 50419-0344-10 | Ultravist 300Bayer HealthCare Pharmaceuticals Inc. | 100 × 10 | 100 | 1,000 | $186.00 | ASP | Q1 2021 – Q4 2026 | ListedUltravist |
|---|
| 50419-0344-12 | Ultravist 300Bayer HealthCare Pharmaceuticals Inc. | 125 × 10 | 125 | 1,250 | $232.50 | ASP | Q1 2021 – Q4 2026 | ListedUltravist |
|---|
| 50419-0344-15 | Ultravist 300Bayer HealthCare Pharmaceuticals Inc. | 150 × 10 | 150 | 1,500 | $279.00 | ASP | Q1 2021 – Q4 2026 | ListedUltravist |
|---|
| 50419-0344-21 | Ultravist 300Bayer HealthCare Pharmaceuticals Inc. | 200 × 10 | 200 | 2,000 | $372.00 | ASP | Q1 2021 – Q4 2026 | ListedUltravist |
|---|
| 50419-0344-23 | Ultravist 300Bayer HealthCare Pharmaceuticals Inc. | 200 × 10 | 200 | 2,000 | $372.00 | ASP | Q2 2026 – Q4 2026 | ListedUltravist |
|---|
| 50419-0344-58 | Ultravist 300Bayer HealthCare Pharmaceuticals Inc. | 500 × 8 | 500 | 4,000 | $744.00 | ASP | Q1 2021 – Q4 2026 | ListedUltravist |
|---|
| 50419-0344-65 | Ultravist 300Bayer HealthCare Pharmaceuticals Inc. | 500 × 8 | 500 | 4,000 | $744.00 | ASP | Q2 2026 – Q4 2026 | ListedUltravist |
|---|
| 50419-0346-05 | Ultravist 370Bayer HealthCare Pharmaceuticals Inc. | 50 × 10 | 50 | 500 | $93.00 | ASP | Q1 2021 – Q4 2026 | ListedUltravist |
|---|
| 50419-0346-10 | Ultravist 370Bayer HealthCare Pharmaceuticals Inc. | 100 × 10 | 100 | 1,000 | $186.00 | ASP | Q1 2021 – Q4 2026 | ListedUltravist |
|---|
| 50419-0346-15 | Ultravist 370Bayer HealthCare Pharmaceuticals Inc. | 150 × 10 | 150 | 1,500 | $279.00 | ASP | Q1 2021 – Q4 2026 | ListedUltravist |
|---|
| 50419-0346-20 | Ultravist 370Bayer HealthCare Pharmaceuticals Inc. | 200 × 10 | 200 | 2,000 | $372.00 | ASP | Q1 2021 – Q4 2026 | ListedUltravist |
|---|
| 50419-0346-25 | Ultravist 370Bayer HealthCare Pharmaceuticals Inc. | 250 × 10 | 250 | 2,500 | $465.00 | ASP | Q1 2021 – Q4 2026 | Not found |
|---|
| 50419-0346-28 | Ultravist 370Bayer HealthCare Pharmaceuticals Inc. | 200 × 10 | 200 | 2,000 | $372.00 | ASP | Q2 2026 – Q4 2026 | ListedUltravist |
|---|
| 50419-0346-58 | Ultravist 370Bayer HealthCare Pharmaceuticals Inc. | 500 × 8 | 500 | 4,000 | $744.00 | ASP | Q1 2021 – Q4 2026 | ListedUltravist |
|---|
| 50419-0346-65 | Ultravist 370Bayer HealthCare Pharmaceuticals Inc. | 500 × 8 | 500 | 4,000 | $744.00 | ASP | Q1 2026 – Q4 2026 | ListedUltravist |
|---|
| 00270-1315-25 | Isovue-300Bracco Diagnostics Inc. | 30 × 10 | 30 | 300 | $55.80 | ASP | Q1 2021 – Q4 2026 | ListedIsovue 300 |
|---|
| 00270-1315-35 | Isovue-300Bracco Diagnostics Inc. | 100 × 10 | 100 | 1,000 | $186.00 | ASP | Q1 2021 – Q4 2026 | ListedIsovue 300 |
|---|
| 00270-1315-45 | Isovue-300Bracco Diagnostics Inc. | 200 × 10 | 200 | 2,000 | $372.00 | ASP | Q1 2021 – Q4 2026 | ListedIsovue 300 |
|---|
| 00270-1315-95 | Isovue-300Bracco Diagnostics Inc. | 500 × 6 | 500 | 3,000 | $558.00 | ASP | Q1 2021 – Q4 2026 | ListedIsovue 300 |
|---|
| 00270-1316-35 | Isovue-370Bracco Diagnostics Inc. | 100 × 10 | 100 | 1,000 | $186.00 | ASP | Q1 2021 – Q4 2026 | ListedIsovue 370 |
|---|
| 00270-1316-45 | Isovue-370Bracco Diagnostics Inc. | 200 × 10 | 200 | 2,000 | $372.00 | ASP | Q1 2021 – Q4 2026 | ListedIsovue 370 |
|---|
| 00270-1316-95 | Isovue-370Bracco Diagnostics Inc. | 500 × 6 | 500 | 3,000 | $558.00 | ASP | Q1 2021 – Q4 2026 | ListedIsovue 370 |
|---|
| 00270-1412-15 | Isovue-M-300Bracco Diagnostics Inc. | 15 × 10 | 15 | 150 | $27.90 | ASP | Q1 2021 – Q4 2026 | ListedIsovue-M |
|---|
| 00270-7300-10 | IomeronBracco Diagnostics Inc. | 100 × 56 | 100 | 5,600 | $1,041.60 | ASP | Q2 2023 – Q4 2026 | ListedIomeron |
|---|
| 00270-7300-20 | IomeronBracco Diagnostics Inc. | 200 × 10 | 200 | 2,000 | $372.00 | ASP | Q2 2023 – Q4 2026 | ListedIomeron |
|---|
| 65219-0383-05 | IodixanolFreseniUS Kabi USA, LLC | 50 × 10 | 50 | 500 | $93.00 | ASP | Q1 2023 – Q4 2026 | ListedIodixanol |
|---|
| 65219-0383-10 | IodixanolFreseniUS Kabi USA, LLC | 100 × 10 | 100 | 1,000 | $186.00 | ASP | Q1 2023 – Q4 2026 | ListedIodixanol |
|---|
| 65219-0383-50 | IodixanolFreseniUS Kabi USA, LLC | 150 × 10 | 150 | 1,500 | $279.00 | ASP | Q1 2023 – Q4 2026 | ListedIodixanol |
|---|
| 65219-0383-70 | IodixanolFreseniUS Kabi USA, LLC | 200 × 10 | 200 | 2,000 | $372.00 | ASP | Q1 2023 – Q4 2026 | ListedIodixanol |
|---|
| 00407-1413-10 | Omnipaque 300GE Healthcare Inc. | 10 × 10 | 10 | 100 | $18.60 | ASP | Q1 2021 – Q4 2026 | ListedOmnipaque |
|---|
| 00407-1413-48 | Omnipaque 300 (Novaplus)GE Healthcare Inc. | 500 × 10 | 500 | 5,000 | $930.00 | ASP | Q1 2021 – Q4 2026 | Excluded listingOmnipaque |
|---|
| 00407-1413-53 | Omnipaque 300GE Healthcare Inc. | 125 × 10 | 125 | 1,250 | $232.50 | ASP | Q1 2021 – Q4 2026 | ListedOmnipaque |
|---|
| 00407-1413-59 | Omnipaque 300GE Healthcare Inc. | 30 × 10 | 30 | 300 | $55.80 | ASP | Q1 2021 – Q4 2026 | ListedOmnipaque |
|---|
| 00407-1413-61 | Omnipaque 300GE Healthcare Inc. | 50 × 10 | 50 | 500 | $93.00 | ASP | Q1 2021 – Q4 2026 | ListedOmnipaque |
|---|
| 00407-1413-62 | Omnipaque 300GE Healthcare Inc. | 75 × 10 | 75 | 750 | $139.50 | ASP | Q1 2021 – Q4 2026 | Excluded listingOmnipaque |
|---|
| 00407-1413-63 | Omnipaque 300GE Healthcare Inc. | 100 × 10 | 100 | 1,000 | $186.00 | ASP | Q1 2021 – Q4 2026 | ListedOmnipaque |
|---|
| 00407-1413-65 | Omnipaque 300GE Healthcare Inc. | 150 × 10 | 150 | 1,500 | $279.00 | ASP | Q1 2021 – Q4 2026 | ListedOmnipaque |
|---|
| 00407-1413-66 | Omnipaque 300GE Healthcare Inc. | 200 × 10 | 200 | 2,000 | $372.00 | ASP | Q1 2021 – Q4 2026 | Excluded listingOmnipaque |
|---|
| 00407-1413-68 | Omnipaque 300GE Healthcare Inc. | 500 × 10 | 500 | 5,000 | $930.00 | ASP | Q1 2021 – Q4 2026 | Excluded listingOmnipaque |
|---|
| 00407-1413-69 | Omnipaque 300GE Healthcare Inc. | 125 × 10 | 125 | 1,250 | $232.50 | ASP | Q1 2022 – Q4 2026 | Excluded listingOmnipaque |
|---|
| 00407-1413-72 | Omnipaque 300GE Healthcare Inc. | 500 × 10 | 500 | 5,000 | $930.00 | ASP | Q1 2021 – Q4 2026 | ListedOmnipaque |
|---|
| 00407-1413-86 | Omnipaque 300GE Healthcare Inc. | 50 × 10 | 50 | 500 | $93.00 | ASP | Q1 2021 – Q4 2026 | Excluded listingOmnipaque |
|---|
| 00407-1413-87 | Omnipaque 300GE Healthcare Inc. | 100 × 10 | 100 | 1,000 | $186.00 | ASP | Q1 2021 – Q4 2026 | Excluded listingOmnipaque |
|---|
| 00407-1413-88 | Omnipaque 300GE Healthcare Inc. | 150 × 10 | 150 | 1,500 | $279.00 | ASP | Q1 2021 – Q4 2026 | Excluded listingOmnipaque |
|---|
| 00407-1413-89 | Omnipaque 300GE Healthcare Inc. | 500 × 10 | 500 | 5,000 | $930.00 | ASP | Q1 2021 – Q4 2026 | Excluded listingOmnipaque |
|---|
| 00407-1414-48 | Omnipaque 350 (Novaplus)GE Healthcare Inc. | 500 × 10 | 500 | 5,000 | $930.00 | ASP | Q1 2021 – Q4 2026 | Excluded listingOmnipaque |
|---|
| 00407-1414-72 | Omnipaque 350GE Healthcare Inc. | 500 × 10 | 500 | 5,000 | $930.00 | ASP | Q1 2021 – Q4 2026 | ListedOmnipaque |
|---|
| 00407-1414-76 | Omnipaque 350GE Healthcare Inc. | 125 × 10 | 125 | 1,250 | $232.50 | ASP | Q1 2021 – Q4 2026 | ListedOmnipaque |
|---|
| 00407-1414-82 | Omnipaque 350GE Healthcare Inc. | 50 × 10 | 50 | 500 | $93.00 | ASP | Q1 2021 – Q4 2026 | Excluded listingOmnipaque |
|---|
| 00407-1414-84 | Omnipaque 350GE Healthcare Inc. | 100 × 10 | 100 | 1,000 | $186.00 | ASP | Q1 2021 – Q4 2026 | Excluded listingOmnipaque |
|---|
| 00407-1414-85 | Omnipaque 350GE Healthcare Inc. | 125 × 10 | 125 | 1,250 | $232.50 | ASP | Q1 2021 – Q4 2026 | Excluded listingOmnipaque |
|---|
| 00407-1414-86 | Omnipaque 350GE Healthcare Inc. | 150 × 10 | 150 | 1,500 | $279.00 | ASP | Q1 2021 – Q4 2026 | Excluded listingOmnipaque |
|---|
| 00407-1414-87 | Omnipaque 350GE Healthcare Inc. | 200 × 10 | 200 | 2,000 | $372.00 | ASP | Q1 2021 – Q4 2026 | Excluded listingOmnipaque |
|---|
| 00407-1414-88 | Omnipaque 350GE Healthcare Inc. | 500 × 10 | 500 | 5,000 | $930.00 | ASP | Q1 2021 – Q4 2026 | Excluded listingOmnipaque |
|---|
| 00407-1414-89 | Omnipaque 350GE Healthcare Inc. | 50 × 10 | 50 | 500 | $93.00 | ASP | Q1 2021 – Q4 2026 | ListedOmnipaque |
|---|
| 00407-1414-90 | Omnipaque 350GE Healthcare Inc. | 75 × 10 | 75 | 750 | $139.50 | ASP | Q1 2021 – Q4 2026 | ListedOmnipaque |
|---|
| 00407-1414-91 | Omnipaque 350GE Healthcare Inc. | 100 × 10 | 100 | 1,000 | $186.00 | ASP | Q1 2021 – Q4 2026 | ListedOmnipaque |
|---|
| 00407-1414-93 | Omnipaque 350GE Healthcare Inc. | 150 × 10 | 150 | 1,500 | $279.00 | ASP | Q1 2021 – Q4 2026 | ListedOmnipaque |
|---|
| 00407-1414-94 | Omnipaque 350GE Healthcare Inc. | 200 × 10 | 200 | 2,000 | $372.00 | ASP | Q1 2021 – Q4 2026 | ListedOmnipaque |
|---|
| 00407-1414-95 | Omnipaque 350GE Healthcare Inc. | 125 × 10 | 125 | 1,250 | $232.50 | ASP | Q1 2022 – Q4 2026 | Excluded listingOmnipaque |
|---|
| 00407-1414-98 | Omnipaque 350GE Healthcare Inc. | 500 × 10 | 500 | 5,000 | $930.00 | ASP | Q1 2021 – Q4 2026 | Excluded listingOmnipaque |
|---|
| 00407-2223-16 | Visipaque 320GE Healthcare Inc. | 50 × 10 | 50 | 500 | $93.00 | ASP | Q1 2021 – Q4 2026 | ListedVisipaque |
|---|
| 00407-2223-17 | Visipaque 320GE Healthcare Inc. | 100 × 10 | 100 | 1,000 | $186.00 | ASP | Q1 2021 – Q4 2026 | ListedVisipaque |
|---|
| 00407-2223-19 | Visipaque 320GE Healthcare Inc. | 150 × 10 | 150 | 1,500 | $279.00 | ASP | Q1 2021 – Q4 2026 | ListedVisipaque |
|---|
| 00407-2223-21 | Visipaque 320GE Healthcare Inc. | 200 × 10 | 200 | 2,000 | $372.00 | ASP | Q1 2021 – Q4 2026 | ListedVisipaque |
|---|
| 00407-2223-23 | Visipaque 320GE Healthcare Inc. | 500 × 10 | 500 | 5,000 | $930.00 | ASP | Q1 2021 – Q4 2026 | ListedVisipaque |
|---|
| 00407-2223-62 | Visipaque 320GE Healthcare Inc. | 50 × 10 | 50 | 500 | $93.00 | ASP | Q1 2021 – Q4 2026 | Excluded listingVisipaque |
|---|
| 00407-2223-64 | Visipaque 320GE Healthcare Inc. | 100 × 10 | 100 | 1,000 | $186.00 | ASP | Q1 2021 – Q4 2026 | Excluded listingVisipaque |
|---|
| 00407-2223-66 | Visipaque 320GE Healthcare Inc. | 150 × 10 | 150 | 1,500 | $279.00 | ASP | Q1 2021 – Q4 2026 | Excluded listingVisipaque |
|---|
| 00407-2223-67 | Visipaque 320GE Healthcare Inc. | 200 × 10 | 200 | 2,000 | $372.00 | ASP | Q1 2021 – Q4 2026 | Excluded listingVisipaque |
|---|
| 00019-1323-06 | Optiray 320Liebel-Flarsheim Company LLC | 50 × 25 | 50 | 1,250 | $232.50 | ASP | Q1 2021 – Q4 2026 | ListedOptiray 320 |
|---|
| 00019-1323-11 | Optiray 320Liebel-Flarsheim Company LLC | 100 × 12 | 100 | 1,200 | $223.20 | ASP | Q1 2021 – Q4 2026 | ListedOptiray 320 |
|---|
| 00019-1323-16 | Optiray 320Liebel-Flarsheim Company LLC | 150 × 12 | 150 | 1,800 | $334.80 | ASP | Q1 2021 – Q4 2026 | ListedOptiray 320 |
|---|
| 00019-1323-21 | Optiray 320Liebel-Flarsheim Company LLC | 200 × 12 | 200 | 2,400 | $446.40 | ASP | Q1 2021 – Q4 2026 | ListedOptiray 320 |
|---|
| 00019-1323-52 | Optiray 320Liebel-Flarsheim Company LLC | 50 × 20 | 50 | 1,000 | $186.00 | ASP | Q1 2021 – Q4 2026 | ListedOptiray 320 |
|---|
| 00019-1323-65 | Ioversol Injection 678 MG/MLLiebel-Flarsheim Company LLC | 500 × 6 | 500 | 3,000 | $558.00 | ASP | Q2 2022 – Q4 2026 | ListedOptiray 320 |
|---|
| 00019-1323-78 | Optiray 320Liebel-Flarsheim Company LLC | 50 × 20 | 50 | 1,000 | $186.00 | ASP | Q1 2021 – Q4 2026 | ListedOptiray 320 |
|---|
| 00019-1323-87 | Optiray 320Liebel-Flarsheim Company LLC | 125 × 20 | 125 | 2,500 | $465.00 | ASP | Q1 2021 – Q4 2026 | ListedOptiray 320 |
|---|
| 00019-1323-90 | Optiray 320Liebel-Flarsheim Company LLC | 100 × 20 | 100 | 2,000 | $372.00 | ASP | Q1 2021 – Q4 2026 | ListedOptiray 320 |
|---|
| 00019-1323-95 | Optiray 320Liebel-Flarsheim Company LLC | 75 × 20 | 75 | 1,500 | $279.00 | ASP | Q1 2021 – Q4 2026 | ListedOptiray 320 |
|---|
| 00019-1333-06 | Optiray 350Liebel-Flarsheim Company LLC | 50 × 25 | 50 | 1,250 | $232.50 | ASP | Q1 2021 – Q4 2026 | ListedOptiray 350 |
|---|
| 00019-1333-11 | Optiray 350Liebel-Flarsheim Company LLC | 100 × 12 | 100 | 1,200 | $223.20 | ASP | Q1 2021 – Q4 2026 | ListedOptiray 350 |
|---|
| 00019-1333-16 | Optiray 350Liebel-Flarsheim Company LLC | 150 × 12 | 150 | 1,800 | $334.80 | ASP | Q1 2021 – Q4 2026 | ListedOptiray 350 |
|---|
| 00019-1333-21 | Optiray 350Liebel-Flarsheim Company LLC | 200 × 12 | 200 | 2,400 | $446.40 | ASP | Q1 2021 – Q4 2026 | ListedOptiray 350 |
|---|
| 00019-1333-65 | Ioversol Injection 741 MG/MLLiebel-Flarsheim Company LLC | 500 × 6 | 500 | 3,000 | $558.00 | ASP | Q2 2022 – Q4 2026 | ListedOptiray 350 |
|---|
| 00019-1333-78 | Optiray 350Liebel-Flarsheim Company LLC | 50 × 20 | 50 | 1,000 | $186.00 | ASP | Q1 2021 – Q4 2026 | ListedOptiray 350 |
|---|
| 00019-1333-87 | Optiray 350Liebel-Flarsheim Company LLC | 125 × 20 | 125 | 2,500 | $465.00 | ASP | Q1 2021 – Q4 2026 | ListedOptiray 350 |
|---|
| 00019-1333-90 | Optiray 350Liebel-Flarsheim Company LLC | 100 × 20 | 100 | 2,000 | $372.00 | ASP | Q1 2021 – Q4 2026 | ListedOptiray 350 |
|---|
| 00019-1333-95 | Optiray 350Liebel-Flarsheim Company LLC | 75 × 20 | 75 | 1,500 | $279.00 | ASP | Q1 2021 – Q4 2026 | ListedOptiray 350 |
|---|
| 70436-0126-82 | IodixanolSlate Run Pharmaceuticals | 15 × 10 | 15 | 150 | $27.90 | ASP | Q1 2024 – Q4 2026 | ListedIopamidol |
|---|
| 70436-0127-82 | IopamidolSlate Run Pharmaceuticals | 100 × 10 | 100 | 1,000 | $186.00 | ASP | Q1 2025 – Q4 2026 | ListedIopamidol |
|---|
| 70436-0219-52 | IopamidolSlate Run Pharmaceuticals | 30 × 10 | 30 | 300 | $55.80 | ASP | Q1 2025 – Q4 2026 | ListedIopamidol |
|---|
| 70436-0219-62 | IopamidolSlate Run Pharmaceuticals | 50 × 10 | 50 | 500 | $93.00 | ASP | Q1 2025 – Q4 2026 | ListedIopamidol |
|---|
| 70436-0219-82 | IopamidolSlate Run Pharmaceuticals | 100 × 10 | 100 | 1,000 | $186.00 | ASP | Q1 2025 – Q4 2026 | ListedIopamidol |
|---|